<DOC>
	<DOCNO>NCT01976364</DOCNO>
	<brief_summary>This Phase 3 , long-term open-label extension study evaluate safety , tolerability efficacy tofacitinib subject active PsA previously participate randomized study tofacitinib indication .</brief_summary>
	<brief_title>Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Previous participation qualify PsA study involve tofacitinib Time End Study visit qualify study &gt; 3 month . Pregnant female , breastfeed female female childbearing potential unwilling unable use highly effective birth control duration study one ovulatory cycle thereafter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tofacitinib</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>CP-690550</keyword>
	<keyword>Jak-inhibitor</keyword>
	<keyword>oral treatment</keyword>
	<keyword>psoriasis</keyword>
	<keyword>OPAL BALANCE</keyword>
	<keyword>moderate</keyword>
	<keyword>sever</keyword>
	<keyword>pruritus</keyword>
	<keyword>itch</keyword>
	<keyword>DLQI</keyword>
</DOC>